Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta
Open Access
- 1 February 1988
- journal article
- research article
- Published by Rockefeller University Press in The Journal of cell biology
- Vol. 106 (2) , 451-459
- https://doi.org/10.1083/jcb.106.2.451
Abstract
Transforming growth factor-beta (TGF beta) is a regulator of cellular proliferation which can alter the proteolytic activity of cultured cells by enhancing the secretion of endothelial type plasminogen activator inhibitor and affecting the secretion of plasminogen activators (PAs) in cultured fibroblastic cells. We used the TGF beta-responsive malignant human lung adenocarcinoma cell line A549 to study the relationships between the known TGF beta-induced growth inhibition and the effects of TGF beta on the secretion of PA activity by A549 cells. PA activity was quantitated by caseinolysis assays, and characterized by urokinase mRNA analysis, immunoprecipitation, and zymography assays. PA-inhibitor production was observed in autoradiograms of SDS-polyacrylamide gels and reverse zymography assays. It was found that TGF beta enhanced the production of PA activity by these cells, in accordance with an enhancement of urokinase mRNA levels. A concomitant stimulation of type 1 PA-inhibitor production was also observed in A549 cells in response to TGF beta. In contrast to the observations of A549 cells, TGF beta caused a decrease in the expression of both urokinase and the tissue-type PA mRNA in human embryonic WI-38 lung fibroblasts indicating opposite regulation of the expression of PAs in these cells. The results suggest that TGF beta may play a role in the regulation of the invasive, proteolytically active phenotype of certain lung carcinoma cells.This publication has 60 references indexed in Scilit:
- Plasminogen activator inhibitor type‐1 : reactive center and amino‐terminal heterogeneity determined by protein and cDNA sequencingFEBS Letters, 1986
- Autocrine saturation of pro-urokinase receptors on human A431 cellsCell, 1986
- Hormonal regulation of extracellular plasminogen activators and Mr ∼ 54000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodiesMolecular and Cellular Endocrinology, 1986
- Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate.The Journal of cell biology, 1986
- Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular massFEBS Letters, 1986
- Plasminogen activation and regulation of pericellular proteolysisBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1985
- Phorbol ester and mitogens stimulate human fibroblast secretions of plasmin-activatable plasminogen activator and protease nexin, an antiactivator/antiplasmin.The Journal of cell biology, 1983
- HUMAN FIBROBLASTS PRODUCE INHIBITOR DIRECTED AGAINST PLASMINOGEN ACTIVATOR WHEN TREATED WITH GLUCOCORTICOIDS*Annals of the New York Academy of Sciences, 1981
- A study of proteases and protease-inhibitor complexes in biological fluidsThe Journal of Experimental Medicine, 1978
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970